We have previously demonstrated both in vitro and in vivo that the pharmacological blockade of MEK synergistically potentiates the antitumor effects of ATO in acute myeloid leukemia (AML), CML and multiple myeloma (MM) via activation of multiple apoptotic pathways [13–16]. The gene discussed is MAP2K7; the disease is acute myeloid leukemia.